epoxyquinomicin C

from culture broth of Amycolatopsis sp.; structure in first source

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

1.	Ureteral Obstruction 04/01/2003 - "We determined whether the novel nuclear factor kappa B activation inhibitor dehydroxymethylepoxyquinomicin (DHMEQ), which is derived from epoxyquinomicin C, affects renal inflammatory responses in unilateral ureteral obstruction. "
2.	Neoplasms (Cancer) 06/01/2017 - "Dehydroxymethylepoxyquinomicin (DHMEQ) which is originally developed as an analog of antibiotic epoxyquinomicin C is a specific and potent inhibitor of NF-κB and has been shown to possess promising potential as an anti-inflammatory and anti-tumor agent. "
3.	Necrosis 07/01/2010 - "1. The novel nuclear factor (NF)-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) is a derivative of the antibiotic epoxyquinomicin C from Amycolatopsis sp. that has been found to inhibit tumour necrosis factor (TNF)-alpha-induced activation of NF-kappaB by suppressing nuclear translocation of NF-kappaB. "
4.	Edema (Dropsy) 11/01/1997 - "In contrast to nonsteroidal anti-inflammatory drugs (NSAIDs), epoxyquinomicin C (1-30 mg/kg) had neither an anti-inflammatory effect on carrageenan-induced paw edema in rats nor an analgesic effect on acetic acid-induced writhing in mice. "

1.	dehydroxymethylepoxyquinomicin
2.	NF-kappa B (NF-kB)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Acetic Acid (Vinegar)
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Carrageenan
7.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
8.	Analgesics (Analgesic Drugs)